SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has announced plans to initiate a U.S. Food and Drug Administration IND-enabling GLP toxicology and pharmacology program for its lead candidate, GEP-44. The studies, to be conducted with LabCorp, are designed to assess safety, dosing parameters and biomarkers across multiple species, supporting future Phase I clinical trials. GEP-44 is a GLP-1 agonist peptide targeting Type II diabetes and obesity, conditions affecting millions worldwide.
The advancement of GEP-44 marks a significant step for SureNano as it transitions from a surfactant distributor to a pharmaceutical company. The company acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide with improved tolerability and potential non-injectable delivery. This move positions SureNano in the competitive obesity and metabolic disease market, which has seen increased interest due to the success of existing GLP-1 drugs.
In addition to its scientific progress, SureNano outlined expanded investor outreach initiatives. The company has entered into a strategic agreement with Investor Brand Network (IBN) to leverage its syndication network of more than 5,000 media outlets. This partnership aims to strengthen market awareness and support continued advancement of its therapeutic pipeline. SureNano also noted additional marketing engagements and early-stage discussions to potentially acquire or license intellectual property related to ibogaine-based therapies, a substance being explored for addiction treatment.
The implications of these developments are twofold. First, the initiation of IND-enabling studies brings GEP-44 closer to clinical trials, offering a potential new treatment option for obesity and diabetes. Second, the expanded investor outreach signals the company’s commitment to increasing visibility and attracting investment. As SureNano progresses, stakeholders will be watching for data from the toxicology studies and any updates on the ibogaine-related discussions.
For more information, the full press release is available at https://ibn.fm/a6nGj. Additional updates on SURNF can be found in the company’s newsroom at https://ibn.fm/SURNF.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is SureNano Science Advances GEP-44 Toward Clinical Trials, Expands Investor Outreach.